Review The role of dyslipidemia and statins in venous thromboembolism

Joel G. Ray; Frits R. Rosendaal

Abstract

1 min read

Recent studies have proposed an association between hyperlipidemia and venous thromboembolism (VTE). We review the epidemiological evidence linking dyslipidemia with VTE and examine several possible underlying mechanisms. We discuss the possible role of HMG CoA reductase inhibitors (statins) in the prevention and treatment of VTE and suggest future directions for research.

Related publications

Article2001

The role of dyslipidemia and statins in venous thromboembolism

Joel G. Ray, Frits R. Rosendaal

Trials

Article2016

Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility

Willem M. Lijfering, Joseph S. Biedermann, Marieke J.H.A. Kruip, Frank W.G. Leebeek, Frits R. Rosendaal, Suzanne C. Cannegieter

Expert Review of Hematology

Article2025

Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications

Mariana Pfeferman, Sina Rashedi, Professor Gregory Lip, C. Weber, Michelle L. O’Donoghue, Steven E. Nissen, Stephen J. Nicholls, Pradeep Natarajan, Jorge Plutzky, Peter Libby, Samuel Z. Goldhaber, Gregory Piazza, Behnood Bikdeli

Article2025

Prevalence of cardiovascular risk factors in persons with venous thromboembolism aged fifty years or younger

Eng Soo Yap, Frits R. Rosendaal, Suzanne C. Cannegieter, Luuk J.J. Scheres

Deleted Journal

Article2003

HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells

Wolfgang Dichtl, Jozef Dulak, Matthias Frick, Hannes Alber, Severin P. Schwarzacher, Mikko P.S. Ares, Jan Nilsson, Otmar Pachinger, Franz Weidinger